SciELO - Scientific Electronic Library Online

vol.132 número7Contenido de ADN y sobrevida en el carcinoma subseroso de la vesícula biliar índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Revista médica de Chile

versión impresa ISSN 0034-9887


MANRIQUEZ H, Jorge; DIAZ P, Orlando; BORZONE T, Gisella  y  LISBOA B, Carmen. Spirometric reversibility to Salbutamol in chronic obstructive pulmonary disease (COPD): Differential effects on FEV1 and on lung volumes. Rev. méd. Chile [online]. 2004, vol.132, n.7, pp.787-793. ISSN 0034-9887.

Background: In recent years it has been suggested that in COPD, lung volumes can be modified more than expiratory flows, with bronchodilators. Aim: To study the acute effects of salbutamol on FEV1 and lung volumes at rest. Subjects and Methods: Forty stable COPD patients were studied using a single dose of salbutamol (200 µg). Forced expiratory volumen in 1 second (FEV1), slow vital capacity (SVC), forced vital capacity (FVC), and inspiratory capacity (IC) were measured at baseline and after salbutamol administration. Results: After salbutamol, 39/40 patients exhibited a clinically significant increase in volumes (SVC, FVC or IC ž10% predicted). A significant increase in FEV1 (ž10% predicted) was observed in only 13 patients. Conclusions: Our results demonstrate that changes in lung volumes, and consequently in dynamic lung hyperinflation, take place more frequently than changes in maximal expiratory flows during the spirometric test in patients with COPD. Assessment of spirometric reversibility based only on changes in FEV1 underestimates the effect of bronchodilator drugs in these patients (Rev Méd Chile 2004; 132: 787-93)

Palabras clave : Bronchodilator agents; Pulmonary disease; chronic obstructive; Respiratory functions tests; Spirometry.

        · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons